Optimizing PTCy Dose and Timing

  • STATUS
    Recruiting
  • End date
    May 29, 2026
  • participants needed
    400
  • sponsor
    National Cancer Institute (NCI)
Updated on 7 May 2021
cancer
remission
sirolimus
chronic myeloid leukemia
myeloid leukemia
lymphoid leukemia
fludarabine
hematologic malignancy
blast crisis
mycophenolate mofetil
cyclophosphamide
chronic lymphocytic leukemia
hla-a
lymphoma
myelofibrosis
bone marrow transplant
busulfan
multiple myeloma
hodgkin's disease
cyclosporine
white blood cell count
chronic myelomonocytic leukemia
carbon monoxide
ejection fraction
karnofsky performance status
cell transplantation
myeloablative conditioning
leukemia
hepatitis b surface antigen
mycophenolate
chronic leukemia
chronic myelomonocytic leukaemia
hla typing
allogeneic hematopoietic stem cell transplant

Summary

Background

Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient s body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of PTCy can have the same benefits.

Objective

To see if a lower dose of PTCy will help people with blood cancers have a more successful transplant and fewer side effects.

Eligibility

People ages 12-65 with leukemia, lymphoma, or multiple myeloma that is not curable with standard therapy and is at high risk of returning without transplant, and their healthy adult relatives

Design

Transplant participants will be screened with:

Blood, urine, breathing, and heart tests

Scans

Chest x-ray

Bone marrow samples: A needle inserted into the participant s pelvis will remove marrow and a bone fragment.

Transplant recipients will stay at the hospital and be prepped with chemotherapy over 6 days for the transplant. They will get stem cells through a catheter in the chest or neck. They will get the cyclophosphamide chemotherapy. They will stay in the hospital about 4 more weeks. They will have blood transfusions. They will have frequent blood tests and 2 bone marrow samples within 1 year after the transplant.

Donor participants will be screened with:

Blood, urine, and heart tests

Chest x-ray

Scans

Donor participants will have bone marrow taken from their pelvis or stem cells taken from their blood. For the blood donation, blood will be taken from a vein in one arm, move through a machine to remove white blood cells, and be returned through a vein in the other arm.

Participation will last up to 5 years....

Description

Background
  • Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-haploidentical HCT
  • When clinically translated, the dose (50 mg/kg) and timing (days +3 and +4) of PTCy used were partly extrapolated from murine major histocompatibility complex (MHC)-matched skin allografting models and were partly empirical
  • In both MHC-haploidentical and MHC-disparate murine HCT models, a dose of 25 mg/kg/day was superior to 50 mg/kg/day on days +3 and +4 in terms of GVHD severity and mortality
  • In the MHC-haploidentical HCT model, a dose of 25 mg/kg on day +4 was equivalent to 25 mg/kg/day on days +3 and +4
  • In addition to better GVHD prevention, lower dosing of PTCy is associated with less broad reduction of T-cell numbers after PTCy
    Objective

-Determine whether a dose of PTCy 25 mg/kg on day +3 and +4 or on day +4 only can maintain adequate protection against grade III-IV acute GVHD.

Eligibility
  • Histologically or cytologically confirmed hematologic malignancy with standard indication for allogeneic hematopoietic cell transplantation including one of the
following
  • Acute myeloid leukemia (AML) of intermediate or adverse risk disease by the 2017 European LeukemiaNet criteria in first morphologic complete remission
  • AML of any risk in second or subsequent morphologic complete remission
  • B-cell acute lymphoblastic leukemia in first or subsequent complete remission
  • T-cell acute lymphoblastic leukemia with minimal residual disease detected after first line therapy and/or adverse genetics
  • Myelodysplastic syndrome of intermediate or higher score by the Revised International Prognostic Scoring System (IPSS-R)
  • Primary myelofibrosis of intermediate-2 or higher risk by the Dynamic International Prognostic Scoring System (DIPSS)
  • Chronic myelomonocytic leukemia
  • Chronic myelogenous leukemia resistant to or intolerant of greater than or equal to 3 tyrosine kinase inhibitors or with prior history of accelerated phase or blast crisis
  • B-cell lymphoma including Hodgkin lymphoma that has relapsed within 1 year of completion of primary treatment
  • Chronic lymphocytic leukemia with 17p deletion and/or unmutated IgHV or refractory to or intolerant of both BTK and PI3K inhibitors
  • Mature T or NK neoplasms as defined in the WHO guidelines of sufficient type and severity for allogeneic HCT based on the Prognostic Index for T- cell lymphoma (PIT) score of low-intermediate risk or higher or on recently published clinical practice guidelines
  • Hematologic malignancy of dendritic cell or histiocytic cell type
  • Multiple myeloma, stage III, relapsing after therapy with both a proteasome inhibitor and an immunomodulatory drug (IMiD)
  • Age 15-65.
  • At least one potentially suitable HLA-haploidentical donor.
  • Karnofsky performance score greater than or equal to 60
  • Adequate organ function
Design
  • Open-label, single-center, non-randomized, phase I/II study
  • All patients will receive myeloablative conditioning, HLA-haploidentical bone marrow HCT, and GVHD prophylaxis with PTCy, MMF, and sirolimus.
  • A small pilot of 5 evaluable patients will receive the standard PTCy 50 mg/kg on days +3/+4 to obtain a limited amount of comparative pharmacokinetic and T-cell immunophenotyping and repertoire data
  • Then the study will proceed to a small, two-level [1) 25 mg/kg/day on days +3 and +4, 2) 25 mg/kg on day +4 only] phase I dose de-escalation study based on the standard 3+3 approach
  • Patients will be evaluated for development of grade III-IV acute GVHD (aGVHD) at day +60 as the dose-limiting toxicity and then phase II will proceed with the shorter duration of the days of treatment (+3/+4 or +4) which is associated with 0-1 of 6 patients with grade III- IV aGVHD at day +60 and with the least amount of toxicity
  • Simon optimal two-stage phase II trial design, to rule out excess grade III-IV acute GVHD with this decreased PTCy exposure, will be used in the phase II portion of the study which will enroll an additional 14 patients to see if this lower PTCy exposure is associated with a similar rate of grade III-IV acute GVHD as is expected with 50 mg/kg on days +3/+4

Details
Condition Hematologic Malignancy, Blood disorder, Graft-Versus-Host Disease, Graft-Versus-Host Disease (GVHD), Blood Cancer, Hematologic Cancer, Hematological Disorders, Hematologic Neoplasms, graft versus host disease, graft-versus-host-disease, hematological malignancy, hematologic malignancies, hematological tumor, haematological malignancy, hematological malignancies
Treatment cyclophosphamide, mycophenolate mofetil, busulfan, Fludarabine, Sirolimus
Clinical Study IdentifierNCT03983850
SponsorNational Cancer Institute (NCI)
Last Modified on7 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Do you have any of these conditions: Hematologic Malignancy or haematological malignancy or hematological malignancies or Graft-Versus-Host Disease (GVHD) or Hematological Disorders or he...?
Do you have any of these conditions: hematologic malignancies or Graft-Versus-Host Disease or Hematologic Malignancy or Hematological Disorders or graft versus host disease or hematologic...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: graft versus host disease or Hematological Disorders or Blood Cancer or hematologic malignancies or Blood disorder or hematological malignancies or Gr...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Hematologic Malignancy or graft-versus-host-disease or Hematological Disorders or hematological tumor or hematological malignancy or Hematologic Cance...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Hematologic Cancer or graft versus host disease or hematological malignancies or Hematologic Malignancy or Graft-Versus-Host Disease or hematological ...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: graft-versus-host-disease or Hematologic Cancer or Graft-Versus-Host Disease or graft versus host disease or Blood disorder or hematologic malignancie...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Hematologic Malignancy or Graft-Versus-Host Disease or hematologic malignancies or Graft-Versus-Host Disease (GVHD) or hematological tumor or hematolo...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Graft-Versus-Host Disease (GVHD) or Hematological Disorders or graft versus host disease or graft-versus-host-disease or hematologic malignancies or B...?
Is your age between 12 yrs and 65 yrs?
Is your age between 15 yrs and 65 yrs?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: graft-versus-host-disease or Hematological Disorders or Graft-Versus-Host Disease or Blood disorder or hematologic malignancies or Hematologic Maligna...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: graft versus host disease or Blood Cancer or Hematologic Cancer or hematological malignancy or graft-versus-host-disease or Graft-Versus-Host Disease ...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Graft-Versus-Host Disease (GVHD) or Graft-Versus-Host Disease or Hematologic Neoplasms or hematologic malignancies or haematological malignancy or Hem...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Graft-Versus-Host Disease or Hematologic Malignancy or hematological malignancies or hematologic malignancies or graft versus host disease or hematolo...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Hematologic Malignancy or Graft-Versus-Host Disease (GVHD) or Hematological Disorders or Hematologic Cancer or Blood Cancer or Blood disorder or hemat...?
Is your age between 12 yrs and 65 yrs?
Do you have any of these conditions: Hematologic Malignancy or Hematological Disorders or Blood Cancer or Graft-Versus-Host Disease (GVHD) or Hematologic Neoplasms or Blood disorder or He...?
Gender: Male or Female
Inclusion Criteria - Recipient
Patients must have a histologically or cytologically confirmed hematologic malignancy with standard indication for allogeneic hematopoietic cell transplantation limited to one of the following
Acute myeloid leukemia (AML) of intermediate or adverse risk disease by the 2017 European LeukemiaNet criteria in first morphologic complete remission (<5% blasts in the bone marrow, no detectable abnormal peripheral blasts, and no extramedullary disease)
AML of any risk in second or subsequent morphologic complete remission
B-cell acute lymphoblastic leukemia in first or subsequent complete remission
T-cell acute lymphoblastic leukemia with minimal residual disease detected after first line therapy and/or adverse genetics (no NOTCH1/FBXW7 mutation or presence of N/K-RAS mutation and/or PTEN gene alteration)
Myelodysplastic syndrome of intermediate or higher score by the Revised International Prognostic Scoring System (IPSS-R)
Primary myelofibrosis of intermediate-2 or higher risk by the DIPSS
Chronic myelomonocytic leukemia
Chronic myelogenous leukemia resistant to or intolerant of greater than or equal to 3 tyrosine kinase inhibitors or with history of accelerated phase or blast crisis
B-cell lymphoma including Hodgkin lymphoma that has relapsed within 1 year of completion of primary treatment
Chronic lymphocytic leukemia with 17p deletion and/or unmutated IgHV or refractory to or intolerant of both BTK and PI3K inhibitors
Mature T or NK neoplasms as defined in the WHO guidelines of sufficient type and severity for allogeneic HCT based on the Prognostic Index for T-cell lymphoma (PIT) score of low-intermediate risk or higher or on recently published clinical practice guidelines
Hematologic malignancy of dendritic cell or histiocytic cell type
Multiple myeloma, stage III, relapsing after therapy with both a proteasome inhibitor and an immunomodulatory drug (IMiD)
Age 15-65. Patients <18 years old must be at least 50 kg. Note: Because patients 15-17 years old and <50 kg are not able to be cared for on the adult oncology wards and by the investigative team, they are excluded
At least one potentially suitable HLA-haploidentical donor
Karnofsky performance score greater than or equal to 60
Adequate organ function defined as possessing all of the following
Cardiac ejection fraction greater than or equal to 45% by 2D ECHO
Forced expiratory volume-1 (FEV-1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) all of greater than or equal to 50% predicted
Estimated serum creatinine clearance of greater than or equal to 60 ml/minute/1.73m(2) calculated using eGRF in the clinical lab for adults and the Schwartz formula for pediatric subjects
Total bilirubin less than or equal to 2X the upper limit of normal
Alanine aminostransferase and aspartate aminotransferase less than or equal to 3X the upper limit of normal
Myeloablative conditioning is toxic to the developing human fetus and is teratogenic. For this reason, the following measures apply
Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one year post-transplant
Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
WOCBP must have a negative serum or urine pregnancy test within 7 days prior to enrollment
Ability of subject or Legally Authorized Representative to understand and the willingness to sign a written informed consent document. Pediatric patients (<18 years of age) will provide assent, and the parent(s) or legal guardian(s) will provide informed consent
Subjects requiring standard therapies to prepare for HCT should be referred in remission if possible. However, these diseases are often aggressive and require swift evaluation for HCT while concurrently attempting to establish disease control through the administration of standard therapies. If ongoing therapy for the underlying disease outside of the NIH is not in the best interest of the subject according to the clinical judgment of the PI, then the subject may receive up to 2 cycles of standard treatment for his/her underlying hematologic malignancy as a bridge to HCT on this protocol, prior to starting the research phase of the study. The subject must have a Karnofsky performance status of greater than or equal to 60% at the start of the first cycle to proceed. If it becomes apparent that the subject will not be able to proceed to HCT, then he/she must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol
Inclusion Criteria - Related Donor
Related donor deemed suitable and eligible, and willing to donate, per clinical evaluations, who are additionally willing to donate blood, bone marrow, and stool for research. Related donors will be evaluated in accordance with existing institutional Standard Policies and Procedures for determination of eligibility and suitability for clinical donation
Age greater than or equal to 12 years

Exclusion Criteria

Exclusion Criteria - Recipient
Patients who are receiving any other investigational agents. Prior experimental therapies must have been completed at least 4 weeks prior to the date of beginning conditioning
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection excluding controlled fungal infection on appropriate treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, endocrinopathy (significant uncontrolled or untreated hypothyroidism, hyperthyroidism, or adrenal insufficiency), or active psychiatric illness/social situations that would limit compliance with study requirements
None
Prior myeloablative conditioning for autologous or allogeneic HCT
An HLA-matched-sibling donor who is available and willing to donate bone marrow. Note: The patient must have access to HCT using this donor for this to be an exclusion criterion
Pregnant women or women who intend to become pregnant during the study are excluded because myeloablative conditioning is toxic to the developing fetus with the potential for teratogenic or abortifacient effects
The potential for some of the study medications to be transmissible via breast milk of nursing mothers is unknown. Because there is unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued
Active malignancy of non-hematopoietic type (excluding non-melanoma skin cancers) which is: metastatic, or relapsed/refractory to treatment, or locally advanced and not amenable to curative treatment, or limited disease treated with curative intent treatment within the last 2 years. This excludes non-melanoma skin cancers
The severity of the hematologic malignancy does not warrant the potential toxicity of myeloablative allogeneic HCT as judged by the PI
Exclusion Criteria - Related Donor
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note